The Q3 beat and narrowed/raised guidance suggest the coding headwinds may be stabilizing, but YoY revenue is still declining. The AMA CPT code approval for 2028 is a positive long-term catalyst, while the 2027 CMS proposed rate increases (OPPS +12%, ASC +15%) provide medium-term support. Monitor the final 2027 OPPS rule expected in November 2026 and Q4 2026 revenue trajectory for signs of a return to growth.
Price Chart
Executive Summary
Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3.0% sequentially, and adjusted diluted EPS of $0.14, beating the consensus estimate of $0.09. The company narrowed its full-year 2026 revenue guidance to $850M-$860M (from $835M-$875M) and raised its adjusted EPS guidance to $1.20-$1.40. A new Category I CPT code for the Inspire V system was approved by the AMA, effective January 2028, providing long-term reimbursement clarity.
Key Financial Metrics
Key Facts
- Q3 2026 revenue of $206.7M, down 7.9% YoY from $224.5M, up 3.0% sequentially from Q2 2026
- GAAP diluted EPS of $(0.84); adjusted diluted EPS of $0.14, beating consensus of $0.09
- Gross margin improved 20 bps YoY to 86.0% on higher Inspire V mix
- Operating loss of $28.7M (13.9% margin) vs operating income of $9.6M (4.3% margin) in Q3 2025, driven by $24.1M restructuring charges and $7.0M legal settlement
- Adjusted operating income of $1.9M (0.9% margin) vs $10.9M (4.9% margin) in Q3 2025
- Operating cash flow of $46.4M, down from $68.5M in Q3 2025
- Cash, cash equivalents and investments of $453.1M at Sept 30, 2026, up $48.5M from Dec 31, 2025
- Full-year 2026 revenue guidance narrowed to $850M-$860M from prior $835M-$875M
- Full-year 2026 adjusted diluted EPS guidance raised to $1.20-$1.40 from prior $1.05-$1.45
- AMA CPT Editorial Panel approved new Category I CPT code for single-lead HGNS devices (including Inspire V), effective January 1, 2028
- Project Horizon restructuring created $30M of incremental annualized growth investment capacity; ~$25M pre-tax charges expected, ~95% recognized in Q3
- Proposed 2027 CMS reimbursement increases: OPPS +12% YoY, ASC +15% YoY (subject to final rule)
Financial Impact
Revenue decline of 7.9% YoY ($17.8M); adjusted EPS beat consensus by $0.05 (55.6% surprise); restructuring charges of $24.1M; legal settlement of $7.0M
Risk Factors
- Coding and reimbursement uncertainty for Inspire V continues to pressure U.S. revenue through at least 2026
- Revenue declined 7.9% YoY; management expects only low-single-digit growth in 2027
- Restructuring charges of $24.1M and legal settlement of $7.0M weighed on Q3 operating results
- Effective tax rate volatility due to stock-based compensation shortfalls and restructuring-related discrete items
- DOJ civil investigative demand and patent litigation with Nyxoah represent ongoing legal overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001609550-26-000051 |
| Document: q32026investorpresentati.htm | 0001609550-26-000051 |
| Document: insp-20261102.htm | 0001609550-26-000051 |
| Document: 0001609550-26-000051-index-headers.html | 0001609550-26-000051 |
| Document: 0001609550-26-000051-index.html | 0001609550-26-000051 |
| Document: 0001609550-26-000051.txt | 0001609550-26-000051 |
| 8-K Data (Synthetic) | 0001609550-26-000051 |
Track record
16 reports on INSP
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $59.52 Now $59.12 −0.67% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Bearish 4/10 Entry $60.54 to $61.10 Now $59.12 +2.35% ▼ −0.93% −1.29% vs SPY
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $62.31 to $62.11 Now $59.12 −5.12% ▼ −0.32% −1.64% vs SPY
- Nov 9, 20267d ago SC 13G/A Bearish 4/10 Entry $62.31 to $62.11 Now $59.12 +5.12% ▲ +0.32% +1.64% vs SPY
- Nov 2, 202614d ago 8-K Mixed 6/10 Viewing No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $61.90 to $66.61 Now $59.12 −4.49% ▲ +7.61% +5.96% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $68.10 to $67.21 Now $59.12 −13.19% ▼ −1.31% −0.83% vs SPY
- Oct 5, 20266w ago Press Release Neutral 1/10 Entry $68.20 Now $59.12 −13.31% No price data
- Jul 27, 202616w ago 3 Neutral 1/10 Entry $51.97 to $51.07 Now $59.12 +13.76% ▼ −1.73% −0.19% vs SPY
- Jul 24, 202616w ago 8-K Neutral 2/10 Entry $50.93 to $51.97 Now $59.12 +16.08% ▲ +2.04% +1.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers